Vivos Therapeutics Provides Update on Revenue Recognition Review
Detailed Analysis Finds Minimal Impact on Prior Financial Results;
No Previously Reported Revenue to be Lost
Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000;
No Need to Restate Prior Year Financial Statements
Related news for (VVOS)
- Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
- Vivos Therapeutics Secures Medicare Approval for VidaSleep Oral Appliance
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/01/25 08:00 AM
- 24/7 Market News Snapshot 01 July, 2025 – Vivos Therapeutics, Inc. Common Stock (NASDAQ:VVOS)
- Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
